| Recruitment status | Terminated |
| Unique ID issued by UMIN | UMIN000002694 |
| Receipt No. | R000003263 |
| Scientific Title | Genetic testing for von Hippel-Lindau disease |
| Date of disclosure of the study information | 2009/11/01 |
| Last modified on | 2021/05/09 (Ver. 6) |
| Basic information | ||
| Public title | Genetic testing for von Hippel-Lindau disease | |
| Acronym | Genetic testing for von Hippel-Lindau disease | |
| Scientific Title | Genetic testing for von Hippel-Lindau disease | |
| Scientific Title:Acronym | Genetic testing for von Hippel-Lindau disease | |
| Region |
|
|
| Condition | ||
| Condition | von Hippel-Lindau (VHL) disease | |
| Classification by specialty |
|
|
| Classification by malignancy | Others | |
| Genomic information | YES | |
| Objectives | |
| Narrative objectives1 | genetic diagnosis for von Hippel-Lindau (VHL) disease patient |
| Basic objectives2 | Others |
| Basic objectives -Others | genetic diagnoses of presymptomatic family members and patients suspected VHL disease
|
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | germline mutation detection for von Hippel-Lindau disease (VHL) gene |
| Key secondary outcomes | optimal patient follow-up based on the phenotype/genotype correlation study |
| Base | |
| Study type | Observational |
| Study design | |
| Basic design | |
| Randomization | |
| Randomization unit | |
| Blinding | |
| Control | |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | |
| No. of arms | |
| Purpose of intervention | |
| Type of intervention | |
| Interventions/Control_1 | |
| Interventions/Control_2 | |
| Interventions/Control_3 | |
| Interventions/Control_4 | |
| Interventions/Control_5 | |
| Interventions/Control_6 | |
| Interventions/Control_7 | |
| Interventions/Control_8 | |
| Interventions/Control_9 | |
| Interventions/Control_10 | |
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1. patients clinically diagnosed as VHL disease
2. presymptomatic members of VHL families 3. patients suspected VHL disease |
|||
| Key exclusion criteria | none | |||
| Target sample size | 100 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Yokohama City University Graduate School of Medicine | ||||||
| Division name | Urology and Molecular Genetics | ||||||
| Zip code | |||||||
| Address | 3-9 Fukuura, Kanazawa-ku, Yokohama | ||||||
| TEL | 045-787-2679 | ||||||
| masayao@yokohama-cu.ac.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | Yokohama City University Graduate School of Medicine | ||||||
| Division name | Urology and Molecular Genetics | ||||||
| Zip code | |||||||
| Address | 3-9 Fukuura, Kanazawa-ku, Yokohama | ||||||
| TEL | 045-787-2679 | ||||||
| Homepage URL | |||||||
| masayao@med.yokohama-cu.ac.jp | |||||||
| Sponsor | |
| Institute | Yokohama City University Graduate School of Medicine |
| Institute | |
| Department | |
| Funding Source | |
| Organization | none |
| Organization | |
| Division | |
| Category of Funding Organization | Self funding |
| Nationality of Funding Organization | Japan |
| Other related organizations | |
| Co-sponsor | Department of Neurosurgery, Yokohama City University School of Medicine |
| Name of secondary funder(s) | none |
| IRB Contact (For public release) | |
| Organization | |
| Address | |
| Tel | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | 横浜市立大学大学院医学研究科(神奈川県) |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Terminated | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry |
|
||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | 1. characterization of germline mutational patterns in Japanese patients
2. phenotype/genotype correlation analysis in Japanese patients 3. optimal follow-up and treatment protocols for Japanese patients |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://upload.umin.ac.jp/cgi-open-bin/icdr_e/ctr_view.cgi?recptno=R000003263 |